Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.71 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.71 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.71 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.71 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.71 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20271682 | 1.00 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4425960 | 1.00 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4426349 | 1.00 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4430365 | 0.92 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4436527 | 0.92 | PSEN1 (0.71) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4423705 | 0.92 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4427195 | 0.90 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4428617 | 0.90 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4436454 | 0.90 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5093453 | 0.89 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925872-B2 | Methods of treating cochlear synaptopathy | Pipeline Therapeutics, Inc. (US) | 2021-02-23 | — | — | US | claimed |
| EP-3554502-A2 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY | Pipeline Therapeutics, Inc. (US) | 2019-10-23 | — | — | EP | claimed |
| US-20190307746-A1 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY | CONTINEUM THERAPEUTICS, INC. | 2019-10-10 | — | — | US | claimed |
| WO-2018111926-A2 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY | INCEPTION 3, INC. (US) | 2018-06-21 | — | — | WO | claimed |
| EP-1711470-B1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | claimed |
| JP-2007505063-A | — | — | 2007-03-08 | — | — | JP | claimed |
| US-7160875-B2 | Malonamide derivatives | HOFFMANN-LA RACHE INC. (US) | 2007-01-09 | — | — | US | claimed |
| EP-1711470-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-18 | — | — | EP | claimed |
| WO-2005023772-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | claimed |
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | claimed |
| US-20210196712-A1 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY | Pipeline Therapeutics, Inc. | 2021-07-01 | — | — | US | disclosed |
| US-10925872-B2 | Methods of treating cochlear synaptopathy | Pipeline Therapeutics, Inc. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10865188-B2 | Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders | Pipeline Therapeutics, Inc. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865188-B2 | Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders | Pipeline Therapeutics, Inc. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3554502-A2 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY | Pipeline Therapeutics, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-1711470-B1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7160875-B2 | Malonamide derivatives | HOFFMANN-LA RACHE INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1711470-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVTIY OF GAMMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005023772-A1 | MALONAMIDE DERIVATIVES BLOCKING THE ACTIVITY OF GAMA-SECRETASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307746-A1 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY | BACE1, SYPL1, SNAP23 | PSEN1 4/4885PSEN2 7/4885APH1B 50/4885 |
| US-20210196712-A1 | METHODS OF TREATING COCHLEAR SYNAPTOPATHY | BACE1, SYPL1, SNAP23 | PSEN1 4/4885PSEN2 7/4885APH1B 50/4885 |
| US-10865188-B2 | Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders | OTC, NISCH, SLC26A4 | PSEN1 418/4885PSEN2 291/4885APH1B 675/4885 |
| US-10925872-B2 | Methods of treating cochlear synaptopathy | BACE1, SYPL1, SNAP23 | PSEN1 4/4885PSEN2 7/4885APH1B 50/4885 |
| US-20050054633-A1 | secretase inhibitors; therapy for Alzheimer's disease | BACE1, BACE2, APP | PSEN1 6/4885PSEN2 8/4885APH1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.